Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 41NIH 4INDUSTRY 3NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 64Breast Neoplasms 63Lymphoma 58Ovarian Neoplasms 51Leukemia 44Sarcoma 43Prostatic Neoplasms 39Multiple Myeloma 36Head and Neck Neoplasms 36Central Nervous System Neoplasms 36Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 31Carcinoma, Ovarian Epithelial 30Melanoma 29Rectal Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lymphoma, Large B-Cell, Diffuse 26Brain Neoplasms 26Urinary Bladder Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Leukemia, Myeloid, Acute 23Fallopian Tube Neoplasms 23Endometrial Neoplasms 22Glioblastoma 21Adenocarcinoma of Lung 21Lymphoma, Mantle-Cell 18Gliosarcoma 17

Interventions

Cyclophosphamide 2Bevacizumab 2pegfilgrastim 1Trastuzumab 1Taxes 1Epirubicin 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Inflammatory Breast Neoplasms × Clear all
NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NSABP Foundation Inc

Phase 2 Completed
105 enrolled 17 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00856492 2017-06-27

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

SWOG Cancer Research Network

Phase 2 Completed
215 enrolled 13 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡